Last $0.31 SGD
Change Today +0.01 / 3.33%
Volume 9.0M
QTVC On Other Exchanges
Symbol
Exchange
Singapore
OTC US
As of 4:04 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

qt vascular ltd (QTVC) Snapshot

Open
$0.31
Previous Close
$0.30
Day High
$0.32
Day Low
$0.31
52 Week High
06/18/14 - $0.56
52 Week Low
12/1/14 - $0.27
Market Cap
235.6M
Average Volume 10 Days
2.7M
EPS TTM
$-0.06
Shares Outstanding
760.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QT VASCULAR LTD (QTVC)

Related News

No related news articles were found.

qt vascular ltd (QTVC) Related Businessweek News

No Related Businessweek News Found

qt vascular ltd (QTVC) Details

QT Vascular Ltd. is engaged in the design, assembly, and distribution of therapeutic solutions for the minimally invasive treatment of complex vascular diseases primarily in the United States, Europe, Asia, and internationally. It offers various peripheral products, including Chocolate percutaneous transluminal angioplasty (PTA), a balloon catheter for the treatment of blocked arteries; GliderXtreme PTA, a balloon catheter that targets complex lesions in the distal peripheral vasculature; GliderfleX PTA for the treatment of distal peripheral vessels; and coronary products, such as Glider percutaneous transluminal coronary angioplasty, a torqueable angioplasty balloon catheter for managing the treatment of a range of complex lesions. The company is also developing a pipeline of products include Chocolate PTCA balloon catheter for use in heart artery interventions; and other products comprising drug coated chocolate and SILK PTA balloon catheters. QT Vascular Ltd. was incorporated in 2013 and is based in Singapore.

Founded in 2013

qt vascular ltd (QTVC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

qt vascular ltd (QTVC) Key Developments

QT Vascular Ltd. Announces Un-Audited Group Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

QT Vascular Ltd. announced un-audited group earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $3.4 million against $1.3 million, loss from operating activities of $4.6 million compared to $5.2 million, loss before tax of $3.7 million compared to $12.4 million and loss attributable to owners of the company of $3.7 million or $0.005 per basic and diluted share compared to $12.4 million or $0.207 per basic and diluted share, net cash used in operating activities of $8.4 million compared to $3.1 million, purchase of property, plant and equipment of $0.1 million compared to $0.1 million and additions to intangible assets of $1.5 million compared to $1.1 million for the same period a year ago. The increase in revenue was mainly due to an increase in sales of Chocolate PTA Balloon Catheter which is based on an agreed sales price model for this product under US distribution agreement with Cordis and Glider PTCA. For the nine months, the company reported revenue of $9.4 million against $3.0 million, loss from operating activities of $17.3 million compared to $12.8 million, loss before tax of $26.3 million compared to $29.0 million and loss attributable to owners of the company of $26.3 million or $0.053 per basic and diluted share compared to $27.9 million or $1.387 per basic and diluted share, net cash used in operating activities of $19.7 million compared to $8.9 million, purchase of property, plant and equipment of $0.3 million compared to $0.2 million and additions to intangible assets of $3.1 million compared to $2.9 million for the same period a year ago. The increase revenue was mainly due to an increase in sales of Chocolate PTA and Glider PTCA with distributors and direct coronary sales in the United States.

QT Vascular Ltd. Announces Global Expansion of Distribution Agreements

QT Vascular Ltd. announced that it has signed distribution agreements for the sales of its Chocolate PTA® balloon catheter in Italy, Austria, Turkey, and Australia. Designed to deliver optimal results without a permanent implant, Chocolate® PTA represents a breakthrough in PTA balloon catheter design. Its unique Nitinol constraining structure (CS) is designed to facilitate a controlled uniform balloon expansion and disperse expansion forces along an increased contact surface area in order to induce less acute trauma on the vessel wall compared to conventional PTA balloons.

QT Vascular Ltd. Appoints Hoon Ching Sing as Independent Director

Hoon Ching Sing is an Independent Director and the Audit Committee Chairman of QT Vascular Ltd. Jeremy Hoon is currently a business adviser. He is the chief executive officer of JH Advisers Sdn Bhd. Jeremy Hoon has over 31 years of experience in providing audit and advisory services across Asia and beyond.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QTVC:SP $0.31 SGD +0.01

QTVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QTVC.
View Industry Companies
 

Industry Analysis

QTVC

Industry Average

Valuation QTVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.9x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QT VASCULAR LTD, please visit www.qtvascular.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.